Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide. (2020)
Attributed to:
Wellcome Trust MRC Cambridge Stem Cell Institute
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/cancers12123859
PubMed Identifier: 33371210
Publication URI: http://europepmc.org/abstract/MED/33371210
Type: Journal Article/Review
Volume: 12
Parent Publication: Cancers
Issue: 12
ISSN: 2072-6694